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Background: Intravascular continuous glucose monitoring (CGM) may facilitate glycemic control in the intensive
care unit (ICU). We compared the accuracy of a CGM device (OptiScanner®) with a standard reference method.
Methods: Adult patients who had blood glucose (BG) levels >150 mg/dl and required insertion of an arterial and
central venous catheter were included. The OptiScanner® was inserted into a multiple-lumen central venous
catheter. Patients were treated using a dynamic-scale insulin algorithm to achieve BG values between 80 and 150
mg/dl. The BG values measured by the OptiScanner® were plotted against BG values measured using a reference
analyzer. The correlation between the BG values measured using the two methods and the clinical relevance of any
differences were assessed using the coefficient of determination (r2) and the Clarke error grid, respectively; bias was
assessed by the mean absolute relative difference (MARD). Three different standards of glucose monitoring were
used to assess accuracy. Glycemic control was assessed using the time in range (TIR). Six indices of glycemic
variability were calculated.
Results: The analysis included 929 paired samples from 88 patients, monitored for a total of 2584 hours. Reference
BG values ranged between 60 and 484 mg/dl. The r2 value was 0.89. The percentage of BG values within zones A
and B of the Clarke error grid was 99.9%; the MARD was 7.7%. Using the ISO 15197 standard and Food and Drug
Administration and consensus standards, respectively, 80.4% of measurements were within 15 mg/dl and 88.2%
within 15% of reference values, 40% of measurements were within 7 mg/dl and 72.5% within 10% of reference
values, and 65.2% of measurements were within 10 mg/dl and 82.7% within 12.5% of reference values. The TIR was
slightly lower with the OptiScanner® than with the reference method. The J-index, standard deviation and maximal
glucose change were the indices of glycemic variability least affected by the measurement device.
Conclusions: Based on the MARD, the performance of the OptiScanner® is adequate for use in ICU patients.
Because recent standards for accuracy were not met, the OptiScanner® should not be used as a sole monitor.
The assessment of glycemic variability is influenced by the time interval between BG determinations.
Trial registration: Clinicaltrials.gov NCT01720381. Registered 31 October 2012.Background
The topic of glycemic control in intensive care unit
(ICU) patients fuels vivid debate. Indeed, some experts
advocate tight glycemic control (TGC) [1] while others
support a “no-touch” approach in cases of stress hyper-
glycemia [2]. Both views are supported by plausible
physiological rationales, although clinical data are highly
controversial [3]. Although retrospective data collected* Correspondence: jean-charles.preiser@erasme.ulb.ac.be
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and synergistic risk factors for increased mortality and
morbidity, prospective studies comparing TGC with lib-
eral glucose control have given divergent results [3, 4].
The survival benefit associated with TGC using intensive in-
sulin therapy reported in the initial landmark study by Van
den Berghe et al. [5] was not confirmed in later multicenter
trials [4, 6–8]. Indeed, the 90-day mortality rate observed in
the largest of these trials [6] was higher in the TGC group
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various factors, including differences in the ability to achieve
the predefined blood glucose target, and an increased inci-
dence of hypoglycemia and higher glycemic variability in-
duced by the intensive insulin therapy.
Achieving TGC or an intermediate level of glycemic
control necessitates a complex multiple-step therapeutic
modality [9], implying that future interventional studies
will need improved treatment strategies [10–12]. Among
recent technological improvements, continuous or near-
continuous intravascular glucose monitoring (CGM) sys-
tems represent a promising means of potentially facilitating
glucose control and decreasing the nursing workload asso-
ciated with TGC. However, validation of available CGM
systems in real-world conditions is a necessary step before
the large-scale dissemination of these devices. In terms of
glucose metrics, replacement of intermittent readings by
CGM-derived data will also require careful reassessment,
as was the case for patients with type I diabetes, in whom
interstitial CGM systems are now widely used.
The aims of the present study were: to validate and as-
sess the accuracy of the latest version of a mid-infrared
spectroscopy-based CGM system (OptiScanner®; Optiscan
Biomedical Corporation, Hayward, CA, USA) designed for
use in the ICU, against a reference blood gas analyzer
method; and to compare glycemic variability indices cal-
culated from intermittent readings and CGM values.Methods
Study design
This study was performed in the 35-bed mixed Depart-
ment of Intensive Care of Erasme University Hospital in
Brussels, Belgium. It was an investigator-initiated study of
critically ill patients who required blood glucose control
with intravenous insulin, according to local policy that
targets a blood glucose level between 80 and 150 mg/dl.
The study was approved by the hospital ethics committee
and patients (or a legal representative) provided written
informed consent before any study-related activity. The
study was registered at Clinicaltrials.gov (NCT 01720381).Study population
Patients were eligible for inclusion if they were aged ≥ 18
years, had an expected ICU stay ≥ 3 days at the time of
enrollment, had an Acute Physiology and Chronic Health
Evaluation (APACHE) II [13] score ≥ 10 within the first 24
hours of ICU admission, had blood glucose measured at
the time of ICU admission > 150 mg/dl and required
insertion of an arterial catheter and a central venous cath-
eter. Included patients were not allowed to participate in
any other concurrent investigational interventional study.
The only exclusion criterion was pregnancy.Glycemic control in the ICU
A computerized dynamic-scale insulin protocol adapted
from Meynaar et al. [14] and operated by nurses is used to
achieve glycemic control in our ICU. The protocol takes
into account the previous blood glucose value, the current
blood glucose value, the current insulin infusion rate and
the carbohydrate intake. After providing this information
to the computer, the protocol recommends therapeutic
changes (insulin bolus and/or infusion rate or amount of
glucose if hypoglycemic) and the time interval for the next
blood glucose check (minimum 6 hourly). Severe hyper-
glycemia was defined as blood glucose > 180 mg/dl, while
severe and mild hypoglycemia were respectively defined as
blood glucose values < 40 and 41–70 mg/dl.Study procedures
Once informed consent had been obtained, a radial or fem-
oral arterial catheter and a 4-lumen jugular or subclavian
central venous catheter (20 cm, 8.5 F; Arrow Int., Morrisville,
NC, USA) were inserted. The OptiScanner® was connected
to a dedicated proximal lumen of the central venous catheter.
The OptiScanner® withdraws 3 ml of blood every 15 mi-
nutes. For each measurement, a sample of 0.1 ml is heparin-
ized and spun in a microcentrifuge, and the plasma sample
is then analyzed by a mid-infrared spectrometer. After
obtaining the absorption spectrum, the system determines
the blood glucose value. The remaining 2.9 ml of blood is
returned to the subject with a small amount of saline. There
is no heparin in the blood returned to the patient.
Arterial blood draws were taken up to 12 times per day,
with at least 1 hour between samples. Each comparative
blood sample was collected at the same time as the OptiS-
canner® was drawing blood from the central venous cath-
eter. The blood glucose in the arterial comparative blood
draw was measured using a YSI 2300 STAT Plus analyzer
(Yellow Spring Instruments, Yellow Spring, OH¸USA).
Two readings were obtained on the same YSI for each sam-
ple. Caregivers were blinded to the OptiScanner® results.
Patients with only one paired sample were excluded
from the analysis.Recorded data
Demographic data (sex, age, ethnicity, history of diabetes
as recorded in the medical file), type of admission (med-
ical, surgical, trauma), APACHE II score, ICU and hos-
pital mortality as well as ICU and hospital lengths of
stay were recorded.
The “down-time” of the OptiScanner® was calculated
as the time without a blood glucose determination,
related to monitor, cartridge or catheter issues, when a
display of blood glucose values was expected. Monitor-
related issues were reported as the no-read rate.
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Individual traces were drawn for each patient. OptiScan-
ner® readings were regressed against paired reference
values using an unweighted least-squares method. The
coefficient of determination (r2) was used to assess the
linearity over the study measurement range and also as a
predictor of glucose prediction error. Bias was assessed
using the mean absolute relative difference (MARD) and
a Bland–Altman plot was drawn to display the mean dif-
ference between OptiScanner® and reference device mea-
surements and the corresponding limits of agreement
(mean bias ± 2.0 × standard deviation (SD) of the bias).
The dispersion of blood glucose values was assessed
using the population coefficient of variation:
PCV ¼ 1 þ 1=4Nð Þ½   CV;
where N is the sample size and CV is the coefficient of
variation.
A Clarke error grid (CEG) [15] was used to calculate the
potential clinical impact of inaccuracies. A CEG is divided
into 10 zones: in the two A zones, the device results are
<20% of the reference results or the results are <70 mg/dl
and the device is considered clinically accurate; in the two
B zones, the device results differ by >20% from the refer-
ence results, but the differences are considered clinically
acceptable because they have little or no effect on treat-
ment decisions; in the C zones, device results differ by
>20% from the reference results, and the differences may
lead to unnecessary treatment; in the D zones, potentially
severe hypoglycemic or hyperglycemic episodes go
undetected; and in the E zones, the devices have opposite
results, leading to conflicting treatment decisions.
Two different standards of glucose monitoring dedi-
cated to the use of point-of-care meters in diabetology
(ISO 15197 2013 and the Food and Drug Administration
(FDA) draft guidance of 2014) and the standard sug-
gested for CGM by a board of experts [10] were used to
assess accuracy. The ISO 15197 states that 95% of mea-
surements must be within 15% or 15 mg/dl of the refer-
ence value (for reference values >100 mg/dl or <100 mg/
dl, respectively). For the FDA determination, 99% of
measurements must be within 10% of the reference
value (if reference value >70 mg/dl) or within 7 mg/dl (if
reference value <70 mg/dl) and 100% of measurements
must be within 20% (if reference value >70 mg/dl) or
within 15 mg/dl (if reference value <70 mg/dl) of the ref-
erence value. Using the consensus standard, 98% of mea-
surements must be within 12.5% or 10 mg/dl of the
reference value (if reference value >100 mg/dl or <100
mg/dl, respectively) and 2% of the remaining measure-
ments must be within 20% of the reference value.
To assess whether indices of performance and variability
were influenced by the time lapse between readings, theintermittent readings determined by the reference device
and CGM values from the OptiScanner® were used to cal-
culate the time in range (TIR; percentage of values within
the 80–150 mg/dl target range) and six indices of glycemic
variability (SD, mean amplitude of glycemic excursions
(MAGE), maximal glucose change (MGC), J-index, glu-
cose variability index (GVI) and glucose lability index
(GLI)) [16–18]. Glycemic variability indices took into ac-
count all of the values registered by the CGM during the
same time interval in which YSI values were obtained.
Correlations and agreements among these measures of
glycemic variability were obtained using Pearson’s correl-
ation coefficient and Bland–Altman methods, respectively.
Data are summarized using means with SD, medians
and interquartile ranges (IQRs), or numbers and percent-
ages. Data were analyzed using IBM® SPSS® Statistics soft-
ware, version 23 for windows and R software, version 3.2.2
(CRAN project). All reported p values are two-sided and
p < 0.05 was considered to indicate statistical significance.
Results
Ninety-eight patients were included between July 2012
and April 2014; 10 were excluded from the analysis (be-
cause of blood-draw issues related to the central venous
catheter (N = 3), removal of an arterial line (N = 2), death
before insertion of the OptiScanner® device (N = 2) and a
small number of paired values (N = 3)), leaving 88 patients
for the final analysis. The characteristics of the patients
are presented in Table 1; 57 (65%) were male, 52 (59%)
were admitted for medical reasons and the median APA-
CHE II score was 19.
A total of 9369 samples (944 paired samples) were
drawn by the CGM device during a monitoring period
of 2584 hours. For 15 pairs of samples no reading was
obtained from the OptiScanner®, leaving a total of 929
pairs for comparison. The “downtime” for the OptiScan-
ner® was 18.9%, including a no-read rate of 7.3%. Some
interferents that had not previously been reported, in-
cluding gelatins (Geloplasma®), were identified during
the study and the concomitant infusion of hydroxyethyl-
starch (Voluven®) and mannitol also interfered with the
OptiScanner®. The interference library, which automatic-
ally adjusts the glucose measurement algorithm for in-
terferences, was updated accordingly. After reanalyzing
the data using the new interference library, and process-
ing the data backwards, the final “no read” rate was
1.6%, yielding a downtime of 13.8%. The OptiScanner®
had to be prematurely disconnected in 12 patients be-
cause of device/catheter-related issues, including cart-
ridge malfunction, occlusion due to blood draw issues
and air in the line.
Blood glucose data calculated from the intermittent ref-
erence readings and from the OptiScanner® are presented
in Table 2. No episodes of severe hypoglycemia were
Table 1 Patient characteristics
Characteristic Value
Male, number (%) 57 (65%)










Subjects with history of diabetes, number (%) 14 (16%)
APACHE II score, median (IQR) 19 (14–26)
ICU mortality, number (%) 17 (19%)
Hospital mortality, number (%) 18 (20%)
ICU LOS (days), median (IQR) 4 (2–8)
Hospital LOS (days), median (IQR) 11 (7–24)
Duration of monitoring with OptiScanner® (hours),
median (IQR)
24 (20–32)
IQR interquartile range, APACHE Acute Physiology and Chronic Health
Evaluation, ICU intensive care unit, LOS length of stay
Table 2 Glucose metrics
Variable YSIa OptiScanner®b
Number of measurements in the ICU 944 929
Number of measurements
per patient, median (IQR)
9 (7–12) 9 (7–12)
Blood glucose level (mg/dl),
median (IQR)
140.5 (122–169) 145 (123–169.5)
Blood glucose level (mg/dl),
mean ± SD
150.6 ± 44.5 150.5 ± 42.2





Patients with severe hypoglycemia,
number (%)
0 0
Measurements of mild hypoglycemia
(41–70 mg/dl), number (%)
5 (0.5%) 6 (0.6%)
Patients with mild hypoglycemia,
number (%)
4 (5%) 3 (3%)
Measurements of severe hyperglycemia
(>180 mg/dl), number (%)
167 (18%) 157 (17%)
Patients with severe hyperglycemia,
number (%)
46 (52%) 47 (53%)
OptiScanner® glucose metrics are based on the measurements that have a
corresponding value for YSI
aYSI 2300 STAT Plus analyzer (Yellow Spring Instruments, Yellow Spring,
OH, USA)
bOptiscan Biomedical Corporation, Hayward, CA, USA
ICU intensive care unit, IQR interquartile range, SD standard deviation
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tected by the OptiScanner®, but not by the YSI, following a
progressive downslope in three patients. More than 50%
of the patients had severe hyperglycemia.
Representative traces from individual patients are
shown in Fig. 1, showing good control over a relatively
prolonged period (Fig. 1a), progressive hypoglycemia
detected by the OptiScanner® and confirmed by the
reference values (Fig. 1b), and a poorly controlled
patient with spikes of hyperglycemia undetected by the
reference device (Fig. 1c).
The correlation between the OptiScanner® blood
glucose and the reference blood glucose was almost linear
(coefficient of determination 0.89; Fig. 2, top panel). The
bias and the limits of agreement were satisfactory, as
reflected by a MARD of 7.7% (Fig. 3) and as shown on theFig. 1 Representative individual traces of blood glucose (BG)
recordings using the OptiScanner® (brown lozenges) and the YSI
blood gas analyzer (yellow squares). Target range delimited by red
lines. a Well-controlled glycemia with 100% in target range with
both methods. b Progressive hypoglycemia detected by the
OptiScanner® and confirmed later by the blood gas analyzer.
c Glycemic excursions detected by the OptiScanner® only, with
blood gas analyzer-based control satisfactory
Fig. 2 Coefficient of determination (r2) and Bland–Altman plot. Top panel Correlation between blood glucose measured by the OptiScanner®
(Y axis) and that measured using the YSI blood gas analyzer (X axis) with a statistically significant p value. Lower panel Bias and limits of
agreement between blood glucose measured by the OptiScanner® (OS) and by the YSI (Bland–Altman method). LLA lower limit of agreement,
ULA upper limit of agreement
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was low (PCV 10.2%). The CEG (Fig. 3) showed good
accuracy of the OptiScanner®, with 95.2% of the results in
zone A and 99.9% of the results in zones A + B.
Using the ISO 15197 2013 standard, 80.4% of OptiScan-
ner® measurements were within 15 mg/dl of reference
values (for reference values <100 mg/dl) and 88.2% of
measurements were within 15% of reference values (for
reference values >100 mg/dl). Using the 2014 FDA draft
guidance, 40% of measurements were within 7 mg/dl of
reference values (for reference values <70 mg/dl) and
72.5% were within 10% of reference values (for referencevalues >70 mg/dl). Using the 2013 consensus recommen-
dation [10], 65.2% of measurements were within 10 mg/dl
of reference values (for reference values <100 mg/dl) and
82.7% of measurements were within 12.5% of reference
values (for reference values >100 mg/dl); also, 95.1% of
measurements deviated less than 20% from the standard
reference value.
The TIR was slightly lower with the OptiScanner® than
with the reference method (55.7% and 59.4%, p < 0.01).
Glucose variability was influenced by the device used for
measurement (Table 3). For each GVI, there was a sig-
nificant correlation (p < 0.01) between values calculated
Fig. 3 Clark error grid. Paired sample values from the OptiScanner® and the blood gas analyzer (black dots). No calls are the number of times that
the device was unable to read the blood glucose value (no reads). PCV population coefficient of variation, MARD mean absolute relative
difference
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OptiScanner®. However, correlations were greater for the
time-independent indices (i.e., J-index, SD and MGC)
than for the time-weighted indices (i.e., GVI and GLI).
Discussion
The present study, performed on a heterogeneous popula-
tion of ICU patients with high disease severity, confirmed
the accuracy, as assessed by the MARD, of the mid-infrared
spectroscopy-based intravascular CGM device, the OptiS-
canner®. The device showed good accuracy and a low bias
over a period up to 32 hours. These findings are consistent
with results published in a former validation study
performed with the same device over shorter periods in 71
patients [19], and with the legal requirements of regulatory
agencies (CEG zones A +B > 99%). Good correlation be-
tween blood glucose values obtained from the OptiScanner®
and those obtained using a reference method has also been
reported in vivo in an animal study [20], in patients with
diabetes [21] and in critically ill patients [19, 22, 23]. CEG
analysis and other techniques, such as the Bland–AltmanTable 3 Accuracy and bias (with limits of agreement) of glycemic v
reference blood gas analyzer
J-index (mg/dl)2 SD (mg/dl) MGC (m
Accuracy Correlation (r)a 0.96 0.94 0.8
Lower limit −16.16 −15.35 −45.1
Bias Mean difference −1.42 −1.81 −1.0
Upper limit 13.32 11.73 43.1
aAll values are statistically significant
SD standard deviation, MGC maximal glucose change, MAGE mean amplitude of glymethod, have been used to assess discrete point-of-care
measurement technologies for a considerable period of time.
However, these techniques do not capture the value of
trends in data and may understate the possible benefit of a
continuous or near-continuous glucose monitor, with the
potential for timely alarms. MARD< 10%, however, supports
the accuracy of the OptiScanner®, implying a low risk of
clinical errors and early detection of hypoglycemia [24, 25].
The OptiScanner® did not meet the requirements for the
ISO 15197 2013 standard, the FDA guidance or the con-
sensus recommendation. However, these standards do not
take into account trend accuracy, which is a potential ad-
vantage of CGM devices. In addition, the ISO and the FDA
standards were created for intermittent monitoring, with
only the consensus standard [10] developed for CGM.
Importantly, the results of the present study were ob-
tained by comparing samples from different sites (arterial
and venous), which may have affected the accuracy, and
after filtering out the effects of several substances that
interfered with the signal detected by the OptiScanner®.
As a result of the adjustment of the algorithm for newariability indices obtained from the OptiScanner® and the
g/dl) MAGE (mg/dl) GVI (mg/dl) per hour GLI (mg/dl) per hour
5 0.72 0.52 0.43
3 −53.30 −0.95 −967.54
1 −3.78 16.54 24.52
0 45.73 34.04 1016.59
cemic excursions, GVI glucose variability index, GLI glucose lability index
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ant that glucose monitoring systems can be adjusted for
chemical confounders or interferents, and the finding of
new interferents and subsequent need for the company to
process data retrospectively highlights the importance of
testing this device in patients receiving different treat-
ments in different institutions.
Interestingly, glycemic control, as assessed by the TIR,
was slightly lower with the CGM device. However, the dif-
ference in TIR between groups, although statistically signifi-
cant, was probably not clinically relevant. Moreover, the TIR
may be greater when CGM is used to guide an insulin
treatment protocol that targets a range narrower than 80–
150 mg/dl. Importantly, some episodes of hypoglycemia
may have been missed by intermittent checks but were
detected by the OptiScanner®, as shown in the example in
Fig. 1c. However, there were no episodes of severe
hypoglycemia, so we are unable to comment on the accur-
acy of the OptiScanner® in this setting. Nevertheless, the
ability to detect hypoglycemia is an important safety issue,
because even short episodes of iatrogenic or spontaneous
hypoglycemia are associated with increased mortality [26].
Glucose variability indices appeared to be differentially
affected by the time intervals between readings. The present
data suggest that J-index, SD and MGC are accurate regard-
less of the measurement frequency and that GVI and GLI
are the most time-influenced indices. Correct interpretation
of indices of glucose variability thus requires knowledge of
the device used to measure the blood glucose values.
The CGM device assessed in this study compares well
with intravascular sensors that use other techniques, in-
cluding enzymatic reactions [27], fluorescence [28, 29] and
microdialysis [30]. One advantage of the OptiScanner® is
that it does not require placement of an additional central
catheter, in contrast to other systems that require periph-
eral venous access [27] or dedicated arterial access [29].
This study has some limitations, including lack of calcu-
lation of the impact of the CGM-based system on nursing
workload or cost-effectiveness and the fact that we were
unable to evaluate the accuracy of the CGM device in the
severe hypoglycemic range. Furthermore, we had some
practical problems with the device, as reflected by the
downtime. Apart from the no reads, the most common
difficulty was occlusion (blood draw and blood return)
followed by the presence of bubbles. Once identified, the
problem was resolved in most cases by flushing the system
or manipulating the catheter. Nevertheless, because of
these interventions and problems related to the cartridge,
we sometimes had to prematurely disconnect the device.
Conclusion
Based on the MARD, the performance of the OptiScanner®
is adequate for use in ICU patients, even though other
standards, initially designed for point-of-care glucosemonitoring devices or suggested for CGM, were not met.
Although problems related to the blood draw system need
to be resolved, this device may represent an important,
minimally invasive means of glucose monitoring in ICU
patients. The assessment of glycemic variability is influ-
enced by the time interval between BG determinations.
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